UPDATE: Cowen Starts Trillium Therapeutics (TRIL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Leerink Partners Starts Trillium Therapeutics (TRIL) at Outperform
April 27, 2015 6:21 AM EDTLeerink Partners initiates coverage on Trillium Therapeutics (NASDAQ: TRIL) with a Outperform rating and a price target of $29.00.
Analyst Michael Schmidt commented, "TRIL is an early stage Biotech company developing SIRPFC which blocks CD47, an emerging immuno-oncology (IO) target which is... More
